Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | QPCT | Q16769 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | FABP1 | P07148 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7177153 | 0.92 | PPARG (0.66) | PPARGPOLBSMN1; SMN2QPCTKMT2A | |
| SCHEMBL9239543 | 0.82 | ALOX15 (0.71) | PPARGPOLBSMN1; SMN2QPCTKMT2A | |
| SCHEMBL14313616 | 0.82 | ALOX15 (0.74) | PPARGPOLBSMN1; SMN2QPCTKMT2A | |
| SCHEMBL12085478 | 0.81 | PPARG (0.62) | PPARGPOLBSMN1; SMN2QPCTKMT2A | |
| SCHEMBL30639808 | 0.81 | PPARG (0.72) | PPARGPOLBSMN1; SMN2QPCTKMT2A | |
| SCHEMBL13949765 | 0.81 | PPARG (0.72) | PPARGPOLBSMN1; SMN2QPCTKMT2A | |
| SCHEMBL2639089 | 0.79 | PPARG (0.72) | PPARGPOLBSMN1; SMN2QPCTKMT2A | |
| SCHEMBL2639086 | 0.79 | PPARG (0.72) | PPARGPOLBSMN1; SMN2QPCTKMT2A | |
| SCHEMBL7468069 | 0.79 | PPARG (0.64) | PPARGPOLBSMN1; SMN2KMT2AALOX15 | |
| SCHEMBL15850340 | 0.78 | PPARG (0.80) | PPARGPOLBSMN1; SMN2QPCTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004339-A1 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004339-A1 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | SSTR4, SSTR1, SSTR3 | PPARG 1628/4885POLB 4464/4885SMN1; SMN2 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.